表紙
市場調査レポート

女性不妊症- パイプライン製品の分析

Women Infertility - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 264088
出版日 ページ情報 英文 209 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.69円で換算しております。
Back to Top
女性不妊症- パイプライン製品の分析 Women Infertility - Pipeline Review, H2 2015
出版日: 2015年12月23日 ページ情報: 英文 209 Pages
概要

女性不妊症とは、避妊をしていないのに1年間にわたり妊娠できない状態であり、女性不妊症には卵管の損傷、ホルモン要因、子宮頸および子宮の要因、原因が分からないもの、など数多くの因子があるとされています。

当レポートでは、女性不妊症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

女性不妊症の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • Actavis plc
  • Merck & Co., Inc.
  • Reliance Life Sciences Pvt. Ltd.
  • あすか製薬
  • Teva Pharmaceutical Industries Limited
  • Zydus Cadila Healthcare Limited
  • Ferring International Center S.A.
  • Pantec Biosolutions AG
  • Access Pharmaceuticals, Inc.
  • Glycotope GmbH
  • PharmaEssentia Corporation
  • PregLem SA
  • Trophogen, Inc.
  • Isifer AB
  • Nora Therapeutics, Inc.
  • Hanmi Pharmaceuticals, Co. Ltd.
  • Finox AG
  • AlphaMab Co., Ltd
  • Dong-A Socio Group

治療薬の評価

  • 単独療法の製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • corifollitropin alfa
    • 製品説明
    • 作用機序
    • 研究開発の進展
  • DR-2011
  • choriogonadotropin alfa biosimilar
  • RTPR-013
  • follitropin alfa biosimilar
  • follitropin alfa biosimilar
  • follitropin delta
  • barusiban
  • Isifera
  • FSH-GEX
  • menotropins
  • kisspeptin
  • NT-100
  • triptorelin
  • Progesterone Vaginal Gel Second Generation
  • AKP-501
  • PGL-1001
  • Biosimilar 4 for Acute Myocardial Infarction and Infertility
  • Oral Fertility Drugs
  • HM-12160B
  • TR-4401
  • Luteinizing Hormone Analog
  • KN-015
  • follitropin alfa biosimilar
  • choriogonadotropin alfa biosimilar
  • Small Molecules for Female Infertility
  • Small Molecule to Agonize FSHR for Infertility
  • FE-999310
  • PEG-FSH
  • Biosimilar 6 for Infertility
  • Biosimilar 5 for Infertility
  • Biosimilar 7 for Infertility and Oncology
  • PGL-3001 - Drug Profile

パイプライン製品の最新動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC6955IDB

Summary

Global Markets Direct's, 'Women Infertility - Pipeline Review, H2 2015', provides an overview of the Women Infertility's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Women Infertility, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Women Infertility and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Women Infertility
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Women Infertility and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Women Infertility products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Women Infertility pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Women Infertility
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Women Infertility pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Women Infertility Overview
  • Therapeutics Development
    • Pipeline Products for Women Infertility - Overview
    • Pipeline Products for Women Infertility - Comparative Analysis
  • Women Infertility - Therapeutics under Development by Companies
  • Women Infertility - Therapeutics under Investigation by Universities/Institutes
  • Women Infertility - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Women Infertility - Products under Development by Companies
  • Women Infertility - Products under Investigation by Universities/Institutes
  • Women Infertility - Companies Involved in Therapeutics Development
    • AbbVie Inc.
    • Addex Therapeutics Ltd
    • Allergan Plc
    • AlphaMab Co., Ltd
    • APAvadis Biotechnologies Srl
    • ASKA Pharmaceutical Co., Ltd.
    • Astellas Pharma Inc.
    • Bayer AG
    • BIOCAD
    • Dong-A Socio Group
    • Dongkook Pharmaceutical Co., Ltd.
    • ElexoPharm GmbH
    • EndoCeutics, Inc.
    • Enteris BioPharma, Inc.
    • Euroscreen S.A.
    • Evotec AG
    • Ferring International Center S.A.
    • Finox AG
    • Forendo Pharma Limited
    • GlaxoSmithKline Plc
    • Glycotope GmbH
    • Kissei Pharmaceutical Co., Ltd.
    • Lipicard Technologies Limited
    • Merrion Pharmaceuticals Plc
    • Nippon Shinyaku Co., Ltd.
    • Nora Therapeutics, Inc.
    • ObsEva SA
    • Orphagen Pharmaceuticals, Inc.
    • Pantec Biosolutions AG
    • PharmaEssentia Corporation
    • Philogen S.p.A.
    • Reliance Life Sciences Pvt. Ltd.
    • Repros Therapeutics Inc.
    • SK Chemicals Co., Ltd.
    • Takeda Pharmaceutical Company Limited
    • TocopheRx, Inc.
    • Trophogen, Inc.
    • ValiRx Plc
    • Viteava Pharmaceuticals, Inc.
    • Zydus Cadila Healthcare Limited
  • Women Infertility - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (anastrozole + levonorgestrel) - Drug Profile
    • acolbifene hydrochloride + prasterone + GnRH agonist - Drug Profile
    • AKP-501 - Drug Profile
    • ASP-1707 - Drug Profile
    • barusiban - Drug Profile
    • BAY-1128688 - Drug Profile
    • bentamapimod - Drug Profile
    • Biosimilar 4 for Acute Myocardial Infarction, Infertility and Thrombosis - Drug Profile
    • Biosimilar 5 for Infertility - Drug Profile
    • Biosimilar 6 for Infertility - Drug Profile
    • Biosimilar 7 for Infertility and Oncology - Drug Profile
    • choriogonadotropin alfa - Drug Profile
    • DKF-301 - Drug Profile
    • DKF-304 - Drug Profile
    • Drug to Inhibit C-Jun for Endometriosis - Drug Profile
    • Drugs for Endometriosis - Drug Profile
    • Drugs for Endometriosis and Uterine Fibroids - Drug Profile
    • elagolix sodium - Drug Profile
    • epelsiban besylate - Drug Profile
    • ESN-364 - Drug Profile
    • EVE-104 - Drug Profile
    • FE-999310 - Drug Profile
    • follitropin alfa - Drug Profile
    • follitropin alfa - Drug Profile
    • follitropin alfa - Drug Profile
    • follitropin alfa (recombinant) - Drug Profile
    • follitropin delta - Drug Profile
    • FP-5677 - Drug Profile
    • FSH-GEX - Drug Profile
    • kisspeptin-54 - Drug Profile
    • KLH-2109 - Drug Profile
    • KN-015 - Drug Profile
    • leuprolide acetate - Drug Profile
    • LM-001 - Drug Profile
    • LM-002 - Drug Profile
    • LT-6121 - Drug Profile
    • menotropins - Drug Profile
    • MER-104 - Drug Profile
    • MIA-602 - Drug Profile
    • Monoclonal Antibody Conjugate to Agonize FSH Receptor for Women Infertility - Drug Profile
    • Monoclonal Antibody to Antagonize Prolactin Receptor for Endometriosis - Drug Profile
    • NCE-403 - Drug Profile
    • NS-580 - Drug Profile
    • NT-100 - Drug Profile
    • OBE-001 - Drug Profile
    • PEG-FSH - Drug Profile
    • Peptides for Cancer and Endometriosis - Drug Profile
    • Peptides to Inhibit Aminopeptidase A for Cancer and Endometriosis - Drug Profile
    • PGL-1001 - Drug Profile
    • PGL-2001 - Drug Profile
    • Progesterone Second Generation - Drug Profile
    • Recombinant Protein for Endometriosis and Ovarian Hyperstimulation Syndrome - Drug Profile
    • Recombinant Protein to Agonize Luteinizing Hormone for Infertility - Drug Profile
    • relugolix - Drug Profile
    • RTPR-013 - Drug Profile
    • S-hCG - Drug Profile
    • SKI-2670 - Drug Profile
    • Small Molecule to Antagonize FSH Receptor for Women's Health - Drug Profile
    • Small Molecules for Female Infertility - Drug Profile
    • Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Uterine Fibroids and Oncology - Drug Profile
    • Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis - Drug Profile
    • Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease - Drug Profile
    • Small Molecules to Inhibit 17 Beta-HSD1 for Endometriosis - Drug Profile
    • Small Molecules to Inhibit 17 Beta-Hydroxysteroid Dehydrogenase Type1 for Endometriosis and Estrogen Dependent Cancers - Drug Profile
    • Small Molecules to Inhibit CD147 for Immunology, Oncology, Endometriosis and Arthritis - Drug Profile
    • SR-16234 - Drug Profile
    • STI-2833 - Drug Profile
    • Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile
    • telapristone acetate - Drug Profile
    • Tetravil - Drug Profile
    • TOP-001 - Drug Profile
    • TOP-002 - Drug Profile
    • TR-4401 - Drug Profile
    • triptorelin - Drug Profile
    • VAL-201 - Drug Profile
    • vilaprisan - Drug Profile
    • VPE-001 - Drug Profile
    • VPEA-004 - Drug Profile
  • Women Infertility - Recent Pipeline Updates
  • Women Infertility - Dormant Projects
  • Women Infertility - Discontinued Products
  • Women Infertility - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Women Infertility, H2 2015
  • Number of Products under Development for Women Infertility - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Development by Companies, H2 2015 (Contd..1)
  • Number of Products under Development by Companies, H2 2015 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Comparative Analysis by Unknown Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Products under Development by Companies, H2 2015 (Contd..2)
  • Products under Development by Companies, H2 2015 (Contd..3)
  • Products under Development by Companies, H2 2015 (Contd..4)
  • Products under Investigation by Universities/Institutes, H2 2015
  • Women Infertility - Pipeline by AbbVie Inc., H2 2015
  • Women Infertility - Pipeline by Addex Therapeutics Ltd, H2 2015
  • Women Infertility - Pipeline by Allergan Plc, H2 2015
  • Women Infertility - Pipeline by AlphaMab Co., Ltd, H2 2015
  • Women Infertility - Pipeline by APAvadis Biotechnologies Srl, H2 2015
  • Women Infertility - Pipeline by ASKA Pharmaceutical Co., Ltd., H2 2015
  • Women Infertility - Pipeline by Astellas Pharma Inc., H2 2015
  • Women Infertility - Pipeline by Bayer AG, H2 2015
  • Women Infertility - Pipeline by BIOCAD, H2 2015
  • Women Infertility - Pipeline by Dong-A Socio Group, H2 2015
  • Women Infertility - Pipeline by Dongkook Pharmaceutical Co., Ltd., H2 2015
  • Women Infertility - Pipeline by ElexoPharm GmbH, H2 2015
  • Women Infertility - Pipeline by EndoCeutics, Inc., H2 2015
  • Women Infertility - Pipeline by Enteris BioPharma, Inc., H2 2015
  • Women Infertility - Pipeline by Euroscreen S.A., H2 2015
  • Women Infertility - Pipeline by Evotec AG, H2 2015
  • Women Infertility - Pipeline by Ferring International Center S.A., H2 2015
  • Women Infertility - Pipeline by Finox AG, H2 2015
  • Women Infertility - Pipeline by Forendo Pharma Limited, H2 2015
  • Women Infertility - Pipeline by GlaxoSmithKline Plc, H2 2015
  • Women Infertility - Pipeline by Glycotope GmbH, H2 2015
  • Women Infertility - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2015
  • Women Infertility - Pipeline by Lipicard Technologies Limited, H2 2015
  • Women Infertility - Pipeline by Merrion Pharmaceuticals Plc, H2 2015
  • Women Infertility - Pipeline by Nippon Shinyaku Co., Ltd., H2 2015
  • Women Infertility - Pipeline by Nora Therapeutics, Inc., H2 2015
  • Women Infertility - Pipeline by ObsEva SA, H2 2015
  • Women Infertility - Pipeline by Orphagen Pharmaceuticals, Inc., H2 2015
  • Women Infertility - Pipeline by Pantec Biosolutions AG, H2 2015
  • Women Infertility - Pipeline by PharmaEssentia Corporation, H2 2015
  • Women Infertility - Pipeline by Philogen S.p.A., H2 2015
  • Women Infertility - Pipeline by Reliance Life Sciences Pvt. Ltd., H2 2015
  • Women Infertility - Pipeline by Repros Therapeutics Inc., H2 2015
  • Women Infertility - Pipeline by SK Chemicals Co., Ltd., H2 2015
  • Women Infertility - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015
  • Women Infertility - Pipeline by TocopheRx, Inc., H2 2015
  • Women Infertility - Pipeline by Trophogen, Inc., H2 2015
  • Women Infertility - Pipeline by ValiRx Plc, H2 2015
  • Women Infertility - Pipeline by Viteava Pharmaceuticals, Inc., H2 2015
  • Women Infertility - Pipeline by Zydus Cadila Healthcare Limited, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Women Infertility Therapeutics - Recent Pipeline Updates, H2 2015
  • Women Infertility - Dormant Projects, H2 2015
  • Women Infertility - Dormant Projects (Contd..1), H2 2015
  • Women Infertility - Dormant Projects (Contd..2), H2 2015
  • Women Infertility - Dormant Projects (Contd..3), H2 2015
  • Women Infertility - Discontinued Products, H2 2015
  • Women Infertility - Discontinued Products (Contd..1), H2 2015

List of Figures

  • Number of Products under Development for Women Infertility, H2 2015
  • Number of Products under Development for Women Infertility - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top